These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 1582985)

  • 1. Cellular and molecular genetic features of myeloma and related disorders.
    Durie BG
    Hematol Oncol Clin North Am; 1992 Apr; 6(2):463-77. PubMed ID: 1582985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromosomes in plasma-cell malignancies.
    Van Den Berghe H
    Eur J Haematol Suppl; 1989; 51():47-51. PubMed ID: 2697595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of bcl-X(L) in the control of apoptosis in murine myeloma cells.
    Gauthier ER; Piché L; Lemieux G; Lemieux R
    Cancer Res; 1996 Mar; 56(6):1451-6. PubMed ID: 8640839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytogenetic and molecular genetic changes in malignant transformation of immortalized esophageal epithelial cells.
    Shen ZY; Xu LY; Chen MH; Cai WJ; Shen J; Chen JY; Zeng Y
    Int J Mol Med; 2003 Aug; 12(2):219-24. PubMed ID: 12851721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular pathogenesis of multiple myeloma.
    Tonon G
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):985-1006, vii. PubMed ID: 17996585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Molecular analysis of multiple myeloma cells].
    Yasuga Y; Hirosawa S
    Nihon Rinsho; 1995 Mar; 53(3):564-7. PubMed ID: 7699886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of LFA-1 surface antigen expression by activated H-ras oncogene in EBV-infected human B-lymphoblast cells.
    Endo K; Borer CH; Tsujimoto Y
    Oncogene; 1991 Aug; 6(8):1391-6. PubMed ID: 1653411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of Ras gene mutations in the context of the molecular heterogeneity of multiple myeloma.
    Intini D; Agnelli L; Ciceri G; Ronchetti D; Fabris S; Nobili L; Lambertenghi-Deliliers G; Lombardi L; Neri A
    Hematol Oncol; 2007 Mar; 25(1):6-10. PubMed ID: 17036375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Genetic abnormalities in lung cancer and their prognostic implications].
    Mitsudomi T; Takahashi T
    Gan To Kagaku Ryoho; 1996 Jul; 23(8):990-6. PubMed ID: 8687234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular genetics of malignant insulinoma.
    Pavelic K; Hrascan R; Kapitanovic S; Vranes Z; Cabrijan T; Spaventi S; Korsic M; Krizanac S; Li YQ; Stambrook P; Gluckman JL; Pavelic ZP
    Anticancer Res; 1996; 16(4A):1707-17. PubMed ID: 8712689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytogenetics and molecular cytogenetics in multiple myeloma.
    Liebisch P; Döhner H
    Eur J Cancer; 2006 Jul; 42(11):1520-9. PubMed ID: 16781866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molecular biology of cell death].
    Tsujimoto Y
    Gan To Kagaku Ryoho; 1994 Apr; 21(5):591-5. PubMed ID: 8154883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetics of multiple myeloma.
    Higgins MJ; Fonseca R
    Best Pract Res Clin Haematol; 2005; 18(4):525-36. PubMed ID: 16026735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ras mutations in human leukemia and related disorders.
    Greenberger JS
    Int J Cell Cloning; 1989 Nov; 7(6):343-59. PubMed ID: 2681441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of chromosome numerical changes in multiple myeloma: fluorescence in situ hybridization analysis using 15 chromosome-specific probes.
    Tabernero D; San Miguel JF; Garcia-Sanz M; Nájera L; García-Isidoro M; Peréz-Simon JA; Gonzalez M; Wiegant J; Raap AK; Orfão A
    Am J Pathol; 1996 Jul; 149(1):153-61. PubMed ID: 8686739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The human breast carcinoma cell line SW 613-S: an experimental system to study tumor heterogeneity in relation to c-myc amplification, growth factor production and other markers (review).
    Lavialle C; Modjtahedi N; Lamonerie T; Frebourg T; Landin RM; Fossar N; Lhomond G; Cassingena R; Brison O
    Anticancer Res; 1989; 9(5):1265-79. PubMed ID: 2686529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease.
    Lombardi L; Poretti G; Mattioli M; Fabris S; Agnelli L; Bicciato S; Kwee I; Rinaldi A; Ronchetti D; Verdelli D; Lambertenghi-Deliliers G; Bertoni F; Neri A
    Genes Chromosomes Cancer; 2007 Mar; 46(3):226-38. PubMed ID: 17171682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiimmunoglobulin inhibition of Burkitt's lymphoma cell proliferation and concurrent reduction of c-myc and mu heavy chain gene expression.
    Arasi VE; Lieberman R; Sandlund J; Kiwanuka J; Novikovs L; Kirsch I; Hollis G; Magrath IT
    Cancer Res; 1989 Jun; 49(12):3235-41. PubMed ID: 2497974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent activation of c-myc and inactivation of bcl-2 by chromosomal translocation in a lymphoblastic lymphoma cell line.
    Kiem HP; Nourse J; Saltman DL; Blume KG; Cleary ML
    Oncogene; 1990 Dec; 5(12):1815-9. PubMed ID: 2284100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular pathogenesis of non-Hodgkin lymphoma: a clinical perspective.
    Gaidano G; Pastore C; Volpe G
    Haematologica; 1995; 80(5):454-72. PubMed ID: 8566891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.